Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AstraZeneca Signs $26.5 Million Deal to Build Production Line in China for Type-2 Diabetes Drug

publication date: Jan 18, 2024

AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone in Jiangsu province to build a new production line in its existing Taizhou manufacturing plant. The agreement calls for the fund to underwrite a new $26.5 million production line for a diabetes therapy that the company launched in China last November. AstraZeneca’s Xigduo XR, a once-daily, fixed dose of dapagliflozin and metformin hydrochloride, is a type-2 diabetes therapy aimed at the large global market for weight loss. AstraZeneca has a large presence in China, which became larger this year after it signed a $1.2 billion deal to acquire China-US CAR-T developer Gracell Biotech. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here